trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Antidepressants are effective in treating ADHD

the verdict
SUPPORTED
the evidence backs this
Recorded sources
8 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Multiple clinical trials, reviews, and meta-analyses demonstrate that certain antidepressants and reuptake inhibitors (such as SNRIs, NDRIs, and multi-reuptake inhibitors like atomoxetine, viloxazine, and centanafadine) effectively treat ADHD symptoms across both pediatric and adult populations.

The analysis

The retrieved literature consistently supports the therapeutic efficacy of various antidepressant classes—specifically serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), and related non-stimulant medications—in managing ADHD symptoms. Multiple clinical trials, systematic reviews, and meta-analyses provide positive evidence, while none of the provided papers refute the premise.

Evidence for · 8
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder
Recorded source metadata

Frank P. Bymaster, Krystyna Golembiowska, Magdalena Kowalska, Yong Kee Choi, Frank I. Tarazi. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder. 2012. https://doi.org/10.1002/syn.21538

EB-1020, a dual norepinephrine and dopamine reuptake inhibitor, successfully decreased immobility in an animal model of depression and reduced hyperactivity in an animal model of ADHD.

See more details
More for · 7
Use of Serotonin Norepinephrine Reuptake Inhibitors in the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatrics
Recorded source metadata

Pauline Park, Joshua Caballero, Hossein Omidian. Use of Serotonin Norepinephrine Reuptake Inhibitors in the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatrics. 2013. https://doi.org/10.1177/1060028013506561

Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, showed patient improvement in pediatric ADHD trials.

What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?
Recorded source metadata

G. Perugi, Ugo De Rosa, M. Barbuti. What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?. 2022. https://doi.org/10.1080/14656566.2022.2148830

Norepinephrine and dopamine reuptake inhibitors act as key nonstimulant medications used to effectively treat ADHD symptoms.

Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.
Recorded source metadata

C. Ward, Ann C. Childress, Na Jin, O. Turkoglu, T. Skubiak, Timothy E. Wilens. Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.. 2025. https://doi.org/10.1016/j.jaac.2025.06.023

Centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhibitor, demonstrated significant efficacy in reducing ADHD symptoms in adolescents.

The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium
Recorded source metadata

Geeta Ilipilla, L. E. Arnold. The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. 2024. https://doi.org/10.1080/14656566.2024.2369197

Adrenergic neurotransmitter reuptake inhibitors provide effective treatment options for ADHD, particularly when patients have comorbid conditions such as depression.

Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.
Recorded source metadata

Xiaojing Hu, Lili Pan, Wenjie Li. Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.. 2022. https://doi.org/10.17219/acem/155802

A meta-analysis confirmed the efficacy of norepinephrine reuptake inhibitors like atomoxetine in treating ADHD.

52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder
Recorded source metadata

G. Mattingly, O. Turkoglu, Denise Chang, Caroline Ward, T. Skubiak, Zhen Zhang, A. Cutler. 52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder. 2025. https://doi.org/10.1097/JCP.0000000000002020

Centanafadine sustained release demonstrated long-term safety and effectiveness in treating adults with ADHD.

Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial.
Recorded source metadata

Adler LA, Lieberman VR, Brijbasi L, Mattingly GW, Yarullina I, Li Y, Earnest J, Rubin J. Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial.. 2026. https://doi.org/10.4088/jcp.25m16234

Viloxazine extended release, a non-stimulant modulating medication, significantly improved ADHD, depression, and anxiety symptoms in adults.

The paper trail · every fact has a biography
first checked01 Aug 2026
judged → SUPPORTED · 8601 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt